Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study

Journal of the National Cancer Institute

Volumn 109, Issue 5, 2017, Pages

  Chang, Su Hsin ^a,b   Luo, Suhong ^a,b   Thomas, Theodore S ^a   O'Brian, Katiuscia K ^a,b   Colditz, Graham A ^b   Carlsson, Nils P ^b   Carson, Kenneth R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLACK PERSON; BODY MASS; CANCER RISK; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OBESITY; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR GROWTH; UNITED STATES; AFRICAN AMERICAN; COMORBIDITY; DISEASE COURSE; ETHNOLOGY; IDEAL BODY WEIGHT; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; OVERWEIGHT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; COMORBIDITY; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDEAL BODY WEIGHT; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 85021351051     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw264     Document Type: Article

References (36)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013.
2. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood. 2009;113(22):5412-5217.
3. Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418-5422.
4. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122(10):3456-3463.
5. Turesson I, Kovalchik SA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123(3): 338-345.
6. Merlini G. Determining the significance of MGUS. Blood. 2014;123(3):305-307.
7. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817.
8. Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120(suppl 12):40-61.
9. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586-2592.
10. Birmann BM, Giovannucci EL, Rosner BA, et al. Regular aspirin use and risk of multiple myeloma: A prospective analysis in the health professionals follow-up study and nurses' health study. Cancer Prev Res (Phila). 2014;7(1): 33-41.
11. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638.
12. Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004;23(38):6365-6378.
13. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6): 556-565.
14. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer-Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798.
15. Beason TS, Colditz GA. Obesity and multiple myeloma. In: Mittelman SD, Berger NA, eds. Energy Balance and Jematologic Malignancies. New York: Springer; 2012:71-95.
16. Hofmann JN, Liao LM, Pollak MN, et al. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood 2012;120(22):4418-20.
17. Bullwinkle EM, Parker MD, Bonan NF, et al. Adipocytes contribute to the growth and progression of multiple myeloma: Unraveling obesity related differences in adipocyte signaling. Cancer Lett. 2016;380(1):114-121.
18. Teras LR, Kitahara CM, Birmann BM, et al. Body size and multiple myeloma mortality: A pooled analysis of 20 prospective studies. Br J Haematol. 2014; 166(5):667-676.
19. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-1079; discussion 1081-1090.
20. Obesity: Preventing and managing the global epidemic. Report of a WHOconsultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
21. Stokes A. Using maximum weight to redefine body mass index categories in studies of the mortality risks of obesity. Popul Health Metr. 2014;12(1):6.
22. Beason TS, Chang SH, Sanfilippo KM, et al. Influence of body mass index on survival in veterans with multiple myeloma. Oncologist. 2013;18(10): 1074-1079.
23. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol. 2003;121(5): 749-757.
24. Savas LS, del Junco DJ, Bastian LA, et al. Mortality ascertainment of women veterans: A comparison of sources of vital status information, 1979-2002. Med Care. 2009;47(1):125-128.
25. Sohn MW, Arnold N, Maynard C, et al. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.
26. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer; 2003.
27. Chang S-H, Luo S, O'Brian KK, et al. Association between metformin use and transformation of monoclonal gammopathy of undetermined significance to multiple myeloma in U.S. veterans with diabetes mellitus: A populationbased cohort study. Lancet Haematol. 2015;2(1):e30-e36.
28. Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer. 2011;47(11):1606-1615.
29. Landgren O, Rajkumar SV, Pfeiffer RM, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010;116(7):1056-1059.
30. De Santis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013;63(3):151-166.
31. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3):904-906.
32. Colditz GA, Bohlke K, Chang S-H, et al. Energy balance and multiple myeloma in African Americans. In: Bowen DJ, Denis GV, Berger NA, eds. Impact of Energy Balance on Cancer Disparities. Switzerland: Springer; 2014:119-129.
33. Agha Z, Lofgren RP, Van Ruiswyk JV, et al. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160(21):3252-3257.
34. Kazis LE, Miller DR, Clark J, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: Results from the Veterans Health Study. Arch Intern Med. 1998;158(6):626-632.
35. Morgan RO, Teal CR, Reddy SG, et al. Measurement in Veterans Affairs health services research: Veterans as a special population. Health Serv Res. 2005; 40(5 Pt 2):1573-1583.
36. Sigurdardottir EE, Turesson I, Lund SH, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1(2):168-174.